Monitoring the rates of composite events with censored data in phase II clinical trials

Biometrics

Volumn 58, Issue 1, 2002, Pages 89-97

  Cheung, Y K ^a   Thall, P F ^b  

^a Columbia University ^*  (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Approximate posterior; Competing risks; Dependent censoring; Historical data; Interim analyses; Mixture of beta distributions

Indexed keywords

PATIENT TREATMENT;

APPROXIMATE POSTERIOR; BETA DISTRIBUTIONS; CENSORED DATA; COMPETING RISKS; COMPOSITE EVENT; DEPENDENT CENSORING; HISTORICAL DATA; INTERIM ANALYSIS; MIXTURE OF BETA DISTRIBUTION; PHASE II;

BAYESIAN NETWORKS;

BAYESIAN ANALYSIS; CANCER; MEDICAL GEOGRAPHY;

ARTICLE; BAYES THEOREM; CLINICAL RESEARCH; CLINICAL TRIAL; DATA ANALYSIS; HUMAN; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; STATISTICAL MODEL;

EID: 0036186030     PISSN: 0006341X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0006-341X.2002.00089.x     Document Type: Article

References (17)

1. Incorporating toxicity considerations into the design of two-stage phase II clinical trials
2. Sequential designs for phase I clinical trials with late-onset toxicities
3. Bivariate sequential designs for phase II trials
4. Estimation and testing in a two-sample generalized odds-rate model
5. One-sample multiple testing procedure for phase II clinical trials
6. Bayesian monitoring of event rates with censored data
7. Bayesian interim analysis of phase II cancer clinical trials
8. Nonparametric estimation from incomplete observations
9. Continual reassessment method: A practical design for phase I clinical trials in cancer
10. The analysis of failure times in the presence of competing risks
11. Parametric likelihoods for multiple nonfatal competing risks and death
12. Optimal two-stage designs for phase II clinical trials
13. Nonparametric Bayesian estimation of survival curves from incomplete observations
14. Practical Bayesian guidelines for phase IIb clinical trials
15. Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials
16. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes
17. A nonidentifiability aspect of the problem of competing risks